IGC Pharma, Inc. - IGC STOCK NEWS

IGC Pharma (NYSE American: IGC) has announced promising preclinical data for IGC-AD1, its potential Alzheimer's disease treatment. The drug demonstrates the ability to modify tau pathology and improve spatial memory, building on previous findings of amyloid plaque reduction. Key results include:

1. 10% reduction in the ratio of phosphorylated tau to total tau
2. 35% reduction in GSK3 enzyme expression
3. 50% faster improvement in spatial memory tests

IGC-AD1 is currently in a Phase 2 clinical trial for agitation in Alzheimer's, with over 1,000 oral doses administered and no dose-limiting adverse events observed. The company aims to position IGC-AD1 for two large indications: agitation in Alzheimer's and as a disease-modifying anti-amyloid/anti-tangle treatment.

IGC Pharma (NYSE American: IGC) is advancing its proprietary formulation, IGC-AD1, toward clinical trials as a potential anti-amyloid disease-modifying treatment for Alzheimer's disease. Following FDA approvals of anti-amyloid drugs in 2023, IGC-AD1 shows promise with its oral administration and strong safety profile. Preliminary data suggests IGC-AD1 may reduce plaque aggregation by ~20% and decrease production by up to 40% without affecting essential Amyloid Precursor Protein (APP) production. The company plans to initiate disease-modifying investigational trials in early 2025, positioning itself in a significant market opportunity. IGC-AD1 is currently in Phase 2 clinical trials for treating agitation in Alzheimer's dementia.

IGC Pharma (NYSE American: IGC) held its Annual Meeting of Stockholders on August 23, 2023, where all proposals disclosed in the Definitive Proxy Statement were approved. Key decisions include:

• Election of Richard Prins and Terry Lierman as Class B directors until the 2027 annual meeting
• Ratification of Manohar Chowdhry & Associates as the independent registered public accounting firm for fiscal year 2025
• Approval to grant 5,000,000 shares of common stock to current and new employees, advisors, directors, and consultants, subject to performance metrics set by the board or CEO

Only stockholders of record as of June 28, 2024, were eligible to vote at the meeting.

IGC Pharma (NYSE American: IGC) has announced promising preclinical research on IGC-1C, a novel small-molecule modulator. The findings reveal that IGC-1C targets tau protein phase separation, offering new possibilities for treating neurodegenerative diseases. Additionally, IGC-1C has been identified as a potential GLP-1 receptor agonist, showing promise for weight loss treatments and presenting a unique strategy to combat Alzheimer's disease.

Key points:

• IGC-1C exhibits a dissociation constant (Kd) of 3.95 ± 0.32 μM with tau, indicating strong binding affinity
• The molecule effectively inhibits tau condensates and prevents their transition into toxic fibrils
• IGC-1C's dual action targets both tau and GLP-1 receptors, potentially addressing multiple pathways in Alzheimer's and metabolic disorders
• The company aims to advance IGC-1C through future clinical trials

IGC Pharma (NYSE American: IGC) has announced that its proprietary molecule, IGC-1A, has been identified as a potential GLP-1 agonist through AI modeling. This discovery marks a significant milestone for the company, potentially expanding its portfolio to include metabolic disorders and weight loss treatments. GLP-1 agonists are known for managing blood sugar levels and promoting weight loss, with potential neuroprotective benefits for Alzheimer's disease.

CEO Ram Mukunda highlighted that IGC-1A and IGC-1C could become effective options for metabolic disorders, comparing favorably to established drugs like Ozempic and Metformin. The company plans to progress with toxicology and dosing studies in 2024, aiming to submit an Investigational New Drug Application to the FDA for IGC-1A.

IGC Pharma reported its Q1 FY2025 results, highlighting significant progress in its Alzheimer's research portfolio. The company's lead drug candidate, IGC-AD1, showed promising interim data in its Phase 2 clinical trial for agitation in Alzheimer's. Additionally, TGR-63 demonstrated positive pre-clinical results in an Alzheimer's mouse model. Despite these advancements, IGC's revenue decreased by 51% to $272,000 compared to the same period last year. The company's R&D expenses increased by 19% to $889,000, reflecting the expansion of clinical trials. The net loss for the quarter was $2.4 million or $0.03 per share. IGC also extended its $12 million loan agreement with O-Bank for another year.

IGC Pharma (NYSE American: IGC) has announced that Alliance Global Partners (AGP) has initiated analyst coverage on the company's common stock with a 'Buy' recommendation and a $3.50 price target. This coverage represents an independent analysis of IGC Pharma's potential in the market. The company emphasizes that the views expressed in the analyst report are those of AGP and not necessarily reflective of IGC Pharma's own perspectives. IGC Pharma also clarifies that it is not responsible for the content, accuracy, or timeliness of the information provided by analysts. Interested parties can access the full analyst report directly from Alliance Global Partners through a provided link.

IGC Pharma has announced promising preclinical data for its drug candidate TGR-63, targeting Alzheimer’s disease. Studies indicate that TGR-63 can cross the blood-brain barrier, a critical challenge in treating Alzheimer's, as confirmed through mass spectrometry and an octanol-water assay. The drug also demonstrated a favorable safety profile, with no adverse effects observed in mice after eight months. The company plans to advance TGR-63 into clinical trials, presenting it as a potential safer alternative to existing treatments. IGC is also exploring other disease targets using AI-driven analyses.

IGC Pharma announced promising preclinical results for its Alzheimer's therapeutic candidate, TGR-63. In mouse models, TGR-63 demonstrated a significant reduction in amyloid plaques—78% in the cortex and 85% in the hippocampus. This indicates potential for slowing or reversing Alzheimer's progression. TGR-63's effectiveness in disrupting amyloid beta aggregates and promoting neuronal viability was observed in cell cultures. The company plans to begin Phase 1 clinical trials for TGR-63 by 2025. IGC Pharma continues to develop its robust pipeline of Alzheimer's treatments, with a focus on leveraging AI for early disease detection and trial optimization.